Universe Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Universe Pharmaceuticals
UPC Stock  USD 0.42  0.01  2.44%   
Universe Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Universe Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Universe Pharmaceuticals financial statements helps investors assess Universe Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Universe Pharmaceuticals' valuation are summarized below:
Gross Profit
7.6 M
Profit Margin
(0.69)
Market Capitalization
3.5 M
Enterprise Value Revenue
0.0174
Revenue
26.7 M
We have found one hundred twenty available fundamental trend indicators for Universe Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. Investors should ensure to double-check all of Universe Pharmaceuticals' current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Universe Pharmaceuticals Total Revenue

39.03 Million

Check Universe Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Universe Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 1.6 M, Depreciation And Amortization of 413.1 K or Interest Expense of 153.8 K, as well as many indicators such as Price To Sales Ratio of 1.75, Dividend Yield of 0.0096 or PTB Ratio of 1.43. Universe financial statements analysis is a perfect complement when working with Universe Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Universe Pharmaceuticals Correlation against competitors.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

Universe Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets47.2 M61.3 M38.5 M
Slightly volatile
Short and Long Term Debt Total3.9 M6.3 M3.5 M
Slightly volatile
Other Current Liabilities3.2 M2.9 M7.3 M
Slightly volatile
Total Current Liabilities12.8 M15.8 M15.1 M
Slightly volatile
Total Stockholder Equity34.4 M45.5 M23.4 M
Slightly volatile
Net Tangible Assets32.4 M53.2 M24.5 M
Slightly volatile
Property Plant And Equipment Net10.6 M17.2 M8.5 M
Slightly volatile
Current Deferred Revenue714.8 K804.2 K876.8 K
Slightly volatile
Retained Earnings13.6 M11.7 M8.1 M
Slightly volatile
Accounts Payable3.8 M5.3 M3.4 M
Slightly volatile
Cash7.1 M6.1 M6.3 M
Very volatile
Non Current Assets Total13.1 M18.9 M10.2 M
Slightly volatile
Other Assets15.6 M14.9 M5.3 M
Slightly volatile
Cash And Short Term Investments14.4 M21.3 M11 M
Slightly volatile
Net Receivables12.2 M12.3 M9.7 M
Slightly volatile
Common Stock Total Equity40 K45 K49.1 K
Slightly volatile
Common Stock Shares Outstanding5.2 M3.3 M12.4 M
Slightly volatile
Liabilities And Stockholders Equity47.2 M61.3 M38.5 M
Slightly volatile
Inventory2.8 M3 M5.4 M
Slightly volatile
Other Current Assets3.7 M4.9 M2.1 M
Slightly volatile
Other Stockholder Equity18.1 M33.7 M12.9 M
Slightly volatile
Total Liabilities12.8 M15.8 M15.1 M
Slightly volatile
Net Invested Capital38.4 M51.8 M26.9 M
Slightly volatile
Long Term Investments572.9 K616.8 K704.2 K
Slightly volatile
Property Plant And Equipment Gross12.8 M24.2 M10.2 M
Slightly volatile
Short and Long Term Debt3.9 M6.3 M3.5 M
Slightly volatile
Total Current Assets34.1 M42.3 M28.3 M
Slightly volatile
Accumulated Other Comprehensive Income22.5 K23.6 K2.3 M
Slightly volatile
Capital Stock64.9 K78.2 K57.2 K
Slightly volatile
Net Working Capital21.3 M26.5 M13.3 M
Slightly volatile
Short Term Debt3.9 M6.3 M3.5 M
Slightly volatile
Intangible Assets135.3 K133.7 K169.8 K
Slightly volatile
Common Stock64.9 K78.2 K57.2 K
Slightly volatile
Property Plant Equipment3.7 M3.8 M4.7 M
Slightly volatile
Non Currrent Assets Other1.9 M2 M2.4 M
Slightly volatile

Universe Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision1.6 M2.1 M2 M
Very volatile
Depreciation And Amortization413.1 K457.9 K478 K
Pretty Stable
Interest Expense153.8 K180.3 K155.3 K
Pretty Stable
Selling General Administrative1.8 M2.5 M1.3 M
Slightly volatile
Selling And Marketing Expenses6.2 M7.8 M4.1 M
Slightly volatile
Total Revenue39 M37.2 M32.6 M
Slightly volatile
Gross Profit18 M11.9 M14.5 M
Pretty Stable
Other Operating Expenses32.9 M41.2 M26.3 M
Slightly volatile
Research Development3.7 M5.6 M2.5 M
Slightly volatile
Cost Of Revenue21 M25.3 M18 M
Slightly volatile
Total Operating Expenses12 M15.9 M8.3 M
Slightly volatile
Reconciled Depreciation508 K585.1 K471.4 K
Slightly volatile
Income Tax Expense1.6 M2.1 M2 M
Very volatile

Universe Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.4 M6.6 M6.8 M
Very volatile
Depreciation508 K585.1 K471.4 K
Slightly volatile
Capital Expenditures48.3 K50.8 K944.5 K
Pretty Stable
End Period Cash Flow7.1 M6.1 M6.3 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.751.84165
Slightly volatile
Dividend Yield0.00960.00920.0052
Slightly volatile
PTB Ratio1.431.5478
Slightly volatile
Days Sales Outstanding90.28109105
Slightly volatile
Book Value Per Share6.599.825.0006
Slightly volatile
Average Payables3.3 M3.8 M4 M
Slightly volatile
Capex To Depreciation0.07420.07812.1048
Pretty Stable
PB Ratio1.431.5478
Slightly volatile
EV To Sales1.751.85165
Slightly volatile
Inventory Turnover5.625.924.584
Slightly volatile
Days Of Inventory On Hand78.0163.81125
Slightly volatile
Payables Turnover6.75.525.5967
Pretty Stable
Sales General And Administrative To Revenue0.03570.06180.0379
Slightly volatile
Average Inventory4.2 M2.6 M4.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.06940.140.0671
Slightly volatile
Capex To Revenue0.00120.00120.0209
Pretty Stable
Cash Per Share2.74.592.1673
Slightly volatile
Payout Ratio1.011.911.1785
Slightly volatile
Days Payables Outstanding51.8668.4967.6497
Pretty Stable
Intangibles To Total Assets0.00550.00320.0055
Slightly volatile
Current Ratio2.222.412.0222
Slightly volatile
Tangible Book Value Per Share6.569.784.975
Slightly volatile
Receivables Turnover3.743.463.5481
Slightly volatile
Graham Number14.8218.3811.1485
Slightly volatile
Shareholders Equity Per Share6.599.825.0006
Slightly volatile
Debt To Equity0.170.160.2039
Slightly volatile
Capex Per Share0.01040.0110.2436
Pretty Stable
Average Receivables8 M11.7 M9.2 M
Slightly volatile
Revenue Per Share6.938.025.3341
Slightly volatile
Interest Debt Per Share0.741.40.6339
Slightly volatile
Debt To Assets0.10.120.0959
Pretty Stable
Operating Cycle202203234
Slightly volatile
Price Book Value Ratio1.431.5478
Slightly volatile
Price Earnings To Growth Ratio0.310.3327.051
Very volatile
Days Of Payables Outstanding51.8668.4967.6497
Pretty Stable
Dividend Payout Ratio1.011.911.1785
Slightly volatile
Ebt Per Ebit0.820.980.9992
Very volatile
Company Equity Multiplier1.751.552.1559
Slightly volatile
Total Debt To Capitalization0.140.12180.166
Slightly volatile
Debt Equity Ratio0.170.160.2039
Slightly volatile
Quick Ratio1.982.191.6732
Slightly volatile
Net Income Per E B T0.781.440.954
Slightly volatile
Cash Ratio0.680.440.4735
Slightly volatile
Cash Conversion Cycle131116164
Slightly volatile
Days Of Inventory Outstanding78.0163.81125
Slightly volatile
Days Of Sales Outstanding90.28109105
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.670.861.4268
Pretty Stable
Price To Book Ratio1.431.5478
Slightly volatile
Fixed Asset Turnover2.362.484.6486
Slightly volatile
Debt Ratio0.10.120.0959
Pretty Stable
Price Sales Ratio1.751.84165
Slightly volatile
Asset Turnover1.080.70.9627
Slightly volatile
Gross Profit Margin0.50.370.4504
Slightly volatile
Price Fair Value1.431.5478
Slightly volatile

Universe Fundamental Market Drivers

Cash And Short Term Investments18.5 M

Universe Upcoming Events

9th of February 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About Universe Pharmaceuticals Financial Statements

Universe Pharmaceuticals stakeholders use historical fundamental indicators, such as Universe Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Universe Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Universe Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Universe Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Universe Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue804.2 K714.8 K
Total Revenue37.2 M39 M
Cost Of Revenue25.3 M21 M
Sales General And Administrative To Revenue 0.06  0.04 
Research And Ddevelopement To Revenue 0.14  0.07 
Revenue Per Share 8.02  6.93 
Ebit Per Revenue(0.13)(0.12)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
EBRCentrais Electricas Brasileiras
HEHawaiian Electric Industries
VFCVF Corporation
When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:
How To Invest In Universe
Details
Is Universe Stock a good investment?
Details
What is Universe Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Universe Pharmaceuticals Correlation against competitors.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.82)
Earnings Share
(76.35)
Revenue Per Share
7.351
Quarterly Revenue Growth
(0.30)
Return On Assets
(0.06)
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY